Search

Your search keyword '"Yiğenoğlu, Tuğçe Nur"' showing total 202 results
Start Over Author "Yiğenoğlu, Tuğçe Nur"
202 results on '"Yiğenoğlu, Tuğçe Nur"'

7. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Author

Ozatli, Duzgun, Giden, Aslı Odabaşı, Erkurt, Mehmet Ali, Korkmaz, Serdal, Basci, Semih, Ulas, Turgay, Turgut, Burhan, Yigenoglu, Tugce Nur, Hacibekiroglu, Tuba, Basturk, Abdulkadir, Dal, Mehmet Sinan, Namdaroglu, Sinem, Hindilerden, Fehmi, Hacioglu, Sibel Kabukcu, Cagliyan, Gulsum Akgun, Ilhan, Gul, Kacmaz, Murat, Uysal, Ayşe, Merter, Mustafa, Ekinci, Omer, Dursun, Fadime Ersoy, Tekinalp, Atakan, Demircioglu, Sinan, Sincan, Gulden, Acik, Didar Yanardag, Akdeniz, Aydan, Ucar, Mehmet Ali, Yeral, Mahmut, Ciftciler, Rafiye, Teke, Hava Uskudar, Umit, Elif Gulsum, Karakus, Abdullah, Bilen, Yusuf, Yokus, Osman, Albayrak, Murat, Demir, Cengiz, Okan, Vahap, Serefhanoglu, Songül, Kartı, Sami, Ozkurt, Zubeyde Nur, Eser, Bulent, Aydogdu, Ismet, Kuku, Irfan, Cagirgan, Seckin, Sonmez, Mehmet, Ozet, Gulsum, and Altuntas, Fevzi

Published
2023
Full Text
View/download PDF

17. Convalescent plasma therapy in patients with COVID-19

Author

Altuntas, Fevzi, Ata, Naim, Yigenoglu, Tugce Nur, Bascı, Semih, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroglu, Sinem, Basturk, Abdulkadir, Hacıbekiroglu, Tuba, Dogu, Mehmet Hilmi, Berber, İlhami, Dal, Kursat, Kınık, Kerem, Haznedaroglu, İbrahim, Yılmaz, Fatma Meriç, Kılıç, İsa, Demircioğlu, Sinan, Yosunkaya, Alper, Erkurt, Mehmet Ali, Turgut, Burhan, Caglayan, Murat, and Celik, Osman

Published
2021
Full Text
View/download PDF

18. Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting.

Author

Namdaroğlu, Sinem, Başcı, Semih, Aslan Candır, Burcu, Yaman, Samet, Yiğenoğlu, Tuğçe Nur, Bahsi, Taha, Özcan, Nurgül, Dal, Mehmet Sinan, Kızıl Çakar, Merih, and Altuntaş, Fevzi

Subjects
HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies, NEPHROBLASTOMA, ACUTE myeloid leukemia, STEM cell transplantation
Abstract

Objectives: The Wilms' tumor gene 1 (WT1) plays a critical role in cell development and the regulation of essential genes involved in cell growth and metabolism. In the context of hematopoietic tumors, including acute myeloid leukemia (AML), WT1 has been identified as a potential marker for measurable residual disease (MRD) assessment. Relapse after allogeneic hematopoietic stem cell transplantation (allo-SCT) remains a significant challenge in AML treatment, highlighting the importance of MRD monitoring for risk stratification and treatment decisions. This study aimed to investigate the clinical significance of WT1 as a molecular marker for MRD and its correlation with chimerism in AML patients post-allo-SCT setting. Methods: We have included 58 patients with WT1-expression-positive acute myeloid leukemia (AML) who received allo-SCT in our center between 2016–2022. The exclusion criteria are as follows: not having WT1 polymerase chain reaction (PCR) measurement at diagnosis, not receiving allo-SCT, and not having a serial measurement of WT1 post-transplant. Pre- and post-transplant assessments were made with flow cytometry, WT1 PCR, and bone marrow morphological evaluations. Statistical analyses were carried out to explore correlations between WT1 levels, MRD markers, and chimerism post-transplantation. Results: We found that WT1 had a significant correlation with flow cytometry and bone marrow morphological evaluation, but not with chimerism. Interestingly, high WT1 expressors exhibited a more robust correlation with chimerism compared to the general cohort. The negative predictive value for post-allo-SCT relapse was 91.8% for the whole WT1 cohort; for high WT1 expressors, it was similar, at 87.5%. The negative predictive value for post-allo-SCT relapse was high for the whole WT1 cohort; for high WT1 expressors, it was similar. The WT1 MRD assay showed a high negative predictive value for post-allo-SCT relapse, consistent across both the entire cohort (91.8%) and high WT1 expressors (87.5%). Conclusions: WT1 expression levels may serve as a valuable ancillary marker in MRD assessment and relapse prediction post-allo-SCT in AML patients, particularly for those lacking specific fusion genes or mutations. However, further large-scale, controlled studies are needed to standardize WT1 MRD assays and establish clear guidelines for their clinical application. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Inferior prognosis in poor mobilizing myeloma patients

Author

Yiğenoğlu, Tuğçe Nur, Başcı, Semih, Ulu, Bahar Uncu, Bakırtaş, Mehmet, Kılınç, Ali, Şahin, Derya, Darçın, Tahir, Yıldız, Jale, Baysal, Nuran Ahu, İskender, Dicle, Çakar, Merih Kızıl, Dal, Mehmet Sinan, Hacıbekiroğlu, Tuba, and Altuntaş, Fevzi

Published
2020
Full Text
View/download PDF

23. Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience.

Author

Yaman, Samet, Başci, Semih, Bozan, Ersin, Seçilmiş, Sema, Candir, Burcu Aslan, Yiğenoğlu, Tuğçe Nur, Çakar, Merih Kızıl, Dal, Mehmet Sinan, and Altuntaş, Fevzi

Subjects
STEM cell transplantation, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, BONE marrow transplantation, CYCLOSPORINE
Abstract

Introduction: Cyclosporine‐A (CsA) and post transplantation cyclophosphamide (PTCy) are common agents used for graft versus host disease (GVHD) prophylaxis in Haploidentical hematopoietic cell transplantation (haplo‐HCT). However, the impact of CsA cessation timing in the posttransplant setting on clinical outcomes is uncertain. We aimed to investigate the impact of a novel approach that integrated early CsA cessation with PTCy utilization. Patients and Methods: This study was a single arm retrospective study carried out at a tertiary referral hospital hematology and bone marrow transplantation center between 2009 and 2022. The patients who received haplo‐HCT with ATG, PTCy and CsA as GVHD prophylaxis were included. CsA was planned for cessation starting at day 45 to day 60. Acute and chronic GVHD were evaluated and graded. CsA blood concentrations and its impact on acute and chronic GVHD was evaluated. Results: Thirty‐one patients composed of 19 (61.3%) male and 12 (38.7%) female patients with a median age of 31 years (20–58). Busulfan and TBI based conditioning regimens were the most utilized regimens. The majority of donors were first degree relatives. Stem cell origin was peripheral blood for all patients. GVHD prophylaxis consisted of ATG, CsA and PTCy. Acute GVHD was observed in 9 (29%) cases, whereas chronic GVHD was seen in 3 (9.7%) cases, with 2 of them having overlapping GVHD. Age, gender, number of chemotherapy lines, transplant characteristics, infused CD34 cell count, and engraftment durations were similar among patients with and without GVHD. Patients with GVHD had similar 1st, 2nd, 3rd and 4th week CsA concentrations compared to patients without GVHD (p > 0.05). The presence of GVHD was not associated with worse progression free survival and overall survival (p = 0.6, p = 0.5, respectively). CMV reactivation was more common in the GVHD group. Conclusion: In the current study, we did not find an impact of CsA concentration on GVHD and post‐transplant outcomes in Haplo‐HCT setting. Therefore, together with the use of PTCy, early CsA cessation can be an option; further studies are needed to understand all aspects of this approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Author

Bakırtaş, Mehmet, primary, Dal, Mehmet Sinan, additional, Yiğenoğlu, Tuğçe Nur, additional, Giden, Asli Odabası, additional, Serin, Istemi, additional, Başcı, Semih, additional, Kalpakci, Yasin, additional, Korkmaz, Serdal, additional, Ekinci, Omer, additional, Albayrak, Murat, additional, Basturk, Abdulkadir, additional, Ozatli, Duzgun, additional, Dogu, Mehmet Hilmi, additional, Hacıbekiroglu, Tuba, additional, Çakar, Merih Kızıl, additional, Ulas, Turgay, additional, Miskioglu, Mine, additional, Gulturk, Emine, additional, Eser, Bulent, additional, and Altuntas, Fevzi, additional

Published
2023
Full Text
View/download PDF

30. Uric Acid and Multiple Myeloma, Unexplored Association

Author

Kaçmaz, Murat, primary, Başcı, Semih, additional, Yaman, Samet, additional, Aslan Candir, Burcu, additional, Seçilmiş, Sema, additional, Ilhan, Gül, additional, Yiğenoğlu, Tuğçe Nur, additional, Kızıl Çakar, Merih, additional, Dal, Mehmet Sinan, additional, and Altuntaş, Fevzi, additional

Published
2023
Full Text
View/download PDF

32. Real-world data on the effectiveness and safety of Ixazomib-LenalidomideDexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.

Author

Bakırtaş, Mehmet, Dal, Mehmet Sinan, Yiğenoğlu, Tuğçe Nur, Giden, Asli Odabası, Serin, Istemi, Başcı, Semih, Kalpakci, Yasin, Korkmaz, Serdal, Ekinci, Omer, Albayrak, Murat, Basturk, Abdulkadir, Ozatli, Duzgun, Dogu, Mehmet Hilmi, Hacıbekiroglu, Tuba, Çakar, Merih Kızıl, Ulas, Turgay, Miskioglu, Mine, Gulturk, Emine, Eser, Bulent, and Altuntas, Fevzi

Published
2023
Full Text
View/download PDF

33. The Timing of Granulocyte Colony-Stimulating Factor in Hematopoietic Stem Cell Transplant in the Pandemic.

Author

Kaçmaz, Murat, Başci, Semih, Yiğenoğlu, Tuğçe Nur, Çakar, Merih Kizil, Dal, Mehmet Sinan, and Altuntaş, Fevzi

Subjects
STEM cell factor, GRANULOCYTE-colony stimulating factor, HEMATOPOIETIC stem cells, STEM cell transplantation, GRAFT versus host disease
Abstract

Granulocyte-colony stimulating factors (G-CSF) are used to shorten the duration of neutropenia after hematopoietic cell transplantation (HCT). However, there is no consensus on which days treatment should be started post -transplantation during the COVID-19 pandemic. In this study, we looked at the influence of G-CSF on clinical outcomes on the fifth (GCSFd5) and tenth (G-CSFd10) days following allo-HCT. Our study includes the data of 60 patients (G-CSFd5, n=28 vs GCSFd10, n=32) who underwent HCT with the diagnosis of acute lymphoblastic leukemia (ALL) between 2015 and 2022. Primary outcome is the effect of G-CSF on hospital stay. Secondary outcomes are the development and duration of febrile neutropenia (FEN), neutrophil engraftment (NE), platelet engraftment (PE), engraftment syndrome (ES), acute graft versus host disease (aGVHD), cytomegalovirus (CMV) viremia, and effects on antimicrobial use. Length of hospital stay, 34.5 days vs. 30 days (p=0.19); median NE, 13.85 vs 15.03 days (p=0.007); median PE, 15.5 vs 12 days (p=0.12); ES, 28.5% vs 12.5% (p=0.12); FEN, 85.7% vs 84.3% (p=0.88); aGVHD, 39.2% vs 40.6% (p=0.92); were observed for GCSFd5 and G-CSFd10, respectively. Although starting G-CSF in the early period after allo-HCT shortened the duration of NE, positive effects on clinical outcomes were not observed. On the contrary, the frequency of ES increased in the group that received GCSF early. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Immune Thrombocytopenia: A Disease With Many Unresolved Questions

Author

Yaman, Samet, primary, Aslan Candır, Burcu, additional, Bozan, Ersin, additional, Seçilmiş, Sema, additional, Başcı, Semih, additional, Uncu Ulu, Bahar, additional, Yiğenoğlu, Tuğçe Nur, additional, Kızıl Çakar, Merih, additional, Dal, Mehmet Sinan, additional, and Altuntaş, Fevzi, additional

Published
2022
Full Text
View/download PDF

38. The Views of Patients with Hematological Malignancies About Complementary and Alternative Medicine

Author

Şahin, Derya, primary, Başcı, Semih, additional, Yaman, Samet, additional, Darçın, Tahir, additional, Uncu Ulu, Bahar, additional, Baysal, Nuran Ahu, additional, İskender, Dicle, additional, Yiğenoğlu, Tuğçe Nur, additional, Hacıbekiroğlu, Tuba, additional, Kızıl Çakar, Merih, additional, Dal, Mehmet Sinan, additional, and Altuntaş, Fevzi, additional

Published
2022
Full Text
View/download PDF

39. Transformed Lymphomas: Is It Really Rare ?

Author

Bozan, Ersin, primary, Başcı, Semih, additional, Yaman, Samet, additional, Bozan, Gökcen, additional, Seçilmiş, Sema, additional, Aslan Candır, Burcu, additional, Yiğenoğlu, Tuğçe Nur, additional, Kızıl Çakar, Merih, additional, Dal, Mehmet Sinan, additional, and Altuntaş, Fevzi, additional

Published
2022
Full Text
View/download PDF

40. Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation?

Author

Uncu Ulu, Bahar, primary, Yiğenoğlu, Tuğçe Nur, additional, Şahin, Derya, additional, Başcı, Semih, additional, İskender, Dicle, additional, Adaş, Yasemin, additional, Atasever Akkaş, Ebru, additional, Hacıbekiroğlu, Tuba, additional, Kızıl çakar, Merih, additional, DAL, Mehmet Sinan, additional, and Altuntaş, Fevzi, additional

Published
2021
Full Text
View/download PDF

41. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Author

Uncu Ulu, Bahar, primary, Dal, Mehmet Sinan, additional, Yönal Hindilerden, İpek, additional, Akay, Olga Meltem, additional, Mehtap, Özgür, additional, Büyükkurt, Nurhilal, additional, Hindilerden, Fehmi, additional, Güneş, Ahmet Kürşad, additional, Yiğenoğlu, Tuğçe Nur, additional, Başcı, Semih, additional, Kızıl Çakar, Merih, additional, Yanardağ Açık, Didar, additional, Korkmaz, Serdal, additional, Ulaş, Turgay, additional, Özet, Gülsüm, additional, Ferhanoğlu, Burhan, additional, Nalçacı, Meliha, additional, and Altuntaş, Fevzi, additional

Published
2021
Full Text
View/download PDF

44. Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old

Author

Uncu Ulu, Bahar, primary, Yiğenoğlu, Tuğçe Nur, additional, Başcı, Semih, additional, Bakırtaş, Mehmet, additional, Şahin, Derya, additional, Darçın, Tahir, additional, Yıldız, Jale, additional, Merdin, Alparslan, additional, Baysal, Nuran Ahu, additional, İskender, Dicle, additional, Dal, Mehmet Sinan, additional, Kızıl Çakar, Merih, additional, and Altuntaş, Fevzi, additional

Published
2021
Full Text
View/download PDF

45. Convalescent (Immune) Plasma Therapy in the Treatment of Critical Patients Infected with SARS-Cov-2 Virus

Author

HACIBEKİROĞLU, Tuba, YİĞENOĞLU, Tuğçe Nur, and KALPAKCI, Yasin

Subjects
Medicine, Research and Experimental, Konvelesan Plazma, Tıbbi Araştırmalar Deneysel
Abstract

Çin Halk Cumhuriyeti’nin Wuhan Eyaletinde yarasadan insana bulaş yolu ile tesbit edilen coronavirüs ailesinden Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virüsü çok hızlı bir yayılım göstererek çok kısa bir sürede tüm dünyada etkisini göstermiştir. 11 Şubat 2020 tarihinde bu virüsün yol açtığı hastalığı COVİD-19 olarak adlandıran Dünya Sağlık Örgütü (WHO) 11 Mart 2020 tarihinde bu salgın hastalığı pandemi olarak ilan etmiştir. Konvelesan plazma (KP) tedavisi tarihteki salgın hastalık dönemlerinde kullanılmış, etkili olduğu gösterilmiş bir pasif antikor tedavisidir. Konvelesan plazmanın etki mekanizmaları arasında virüsü direkt bağlayarak nötrolize etmek, kompleman aktivasyonu, antikor bağımlı sellüler sitotoksisite ve/veya fagositoz yollarıyla virüs eliminasyonunu başlatmak sayılabilir. Nötralizan antikorlar bu etki mekanizmalarında çok önemlidir. Virüsü inaktive ederek viral replikasyonu engellemesi iyileşmedeki en önemli noktadır. Bu yüzden KP da nötrolizan antikor titresi ölçümü önemlidir. Nötralizan olmayan antikorların viral replikasyonu durdurmadığı in vitro olarak gösterilmiş ve bu antikorların proflakside kullanılabileceği, iyileşmede destekleyici etkileri olduğu öne sürülmüştür. COVİD-19 hastalığında yapılan çalışmalarda da KP nın etkili olduğu görülmüştür. Ülkemizde ve Amerikada yakın zamanda tedavi endikasyonu alan bu tedavi yönteminin uygulama kriterleri her iki ülke tarafından belirlenmiştir. Uygun donorlerden, fayda görebilecek hastalara nakledilen konvelesan plazma tedavi sonuçları merakla beklenmektedir.

Published
2020

46. Adult aplastic anemia patients can maintain remission after allogeneic hematopoietic stem cell transplantation in a mixed chimeric state

Author

BAŞCI, Semih, YİĞENOĞLU, Tuğçe Nur, BAKIRTAŞ, Mehmet, UNCU ULU, Bahar, ŞAHİN, Derya, DARÇIN, Tahir, YILDIZ, Jale, İSKENDER, Dicle, BAYSAL, Nuran Ahu, DAL, Sinan, KIZIL ÇAKIR, Merih, and ALTUNTAŞ, Fevzi

Subjects
Hematoloji, Hematology, erişkin aplastik anemi,allojenik kök hücre nakli,kimerizm, adult aplastic anemia,allogeneic stem cell transplantation,chimerism
Abstract

Amaç: Allojenik kök hücre nakli (AKHN), uygun vericisi bulunan fit ağır aplastik anemili (SAA) ve çok ağır aplastik anemili (VSAA)hastalarda küratif tedavi yöntemi olarak uygulanmaktadır. Yaş, nakil sonrası sağkalımı belirleyen en önemli faktörlerden biridir ve ilerleyen yaş ile birlikte sağkalım oranları azalmaktadır, bu nedenle uygun hastaların geciktirilmeden nakle alınması büyük önem taşımaktadır. AKHN sonrasında miks kimerizm (MK) olması nüs ya da engraftman yetersizliğinin işareti olabilir. Biz bu çalışmada, erişkin SAA ve VSAA hastalarında AKHN sonrasındaki durumunu ve takipte kimerizmin önemini incelemeyi amaçladık.Yöntemler: Merkezimizde AKHN olan 16 AA hastası bu gözlemsel çalışmaya dahil edildi. HLA durumu, hazırlama rejimi, kimerizm ve remisyon durumu kaydedildi. Bulgular: Tüm hastalarda medyan PFS 70,4 ay ve medyan OS 89,7 ay olarak izlendi. Takip süresi boyunca, 9 hasta tam kimerik iken 6 hasta MK ve 1 hastada kimerizm, Aim: Allogeneic stem cell transplantation (allo-SCT) is performed as a curative treatment in young, fit, severe aplastic anemia (SAA) and very severe aplastic anemia (VSAA) patients. Age is one of the most significant factors that impact survival after transplantation. With advancing age, survival rates decrease, therefore it is crucial to perform allo-SCT without any delay in appropriate SAA and VSAA patients. Mixed chimerism (MC) in the post-allo-SCT period may be a sign of relapse or graft failure. In this study, we aimed to evaluate the outcome of allo-SCT in adult SAA and VSAA patients and the significance of chimerism monitoring in follow up.Methods: The data of 16 adult AA patients who underwent allo-SCT at our center were included in this observational study. HLA match, conditioning regimens, chimerism and remission status were recorded. Results: Median PFS was 70.4 months and median OS was 89.7 months in all patients. During the follow-up period, 9 patients remained fully chimeric whereas 6 patients had MC. The chimerism level of one patient, who had engraftment failure, was

Published
2020

47. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Author

BATGİ, Hikmettullah, primary, BAŞCI, Semih, additional, DAL, Mehmet Sinan, additional, KIZIL ÇAKAR, Merih, additional, UNCU ULU, Bahar, additional, YİĞENOĞLU, Tuğçe Nur, additional, ÖZCAN, Nurgül, additional, KILINÇ, Ali, additional, MERDİN, Alparslan, additional, YILDIZ, Jale, additional, BAKIRTAŞ, Mehmet, additional, ŞAHİN, Derya, additional, DARÇIN, Tahir, additional, İSKENDER, Dicle, additional, BAYSAL, Nuran Ahu, additional, and ALTUNTAŞ, Fevzi, additional

Published
2021
Full Text
View/download PDF

48. Evaluation of seasonality in the diagnosis of diffuse large B cell lymphoma in Turkey

Author

BAKIRTAŞ, Mehmet, primary, UNCU ULU, Bahar, additional, BAŞCI, Semih, additional, DARÇIN, Tahir, additional, ŞAHİN, Derya, additional, YILDIZ, Jale, additional, MERDİN, Alparslan, additional, BATGİ, Hikmetullah, additional, OZCAN, Nurgul, additional, YİĞENOĞLU, Tuğçe Nur, additional, SEÇİLMİŞ, Sema, additional, İSKENDER, Dicle, additional, BAYSAL, Nuran Ahu, additional, KIZIL ÇAKIR, Merih, additional, DAL, Sinan, additional, and ALTUNTAŞ, Fevzi, additional

Published
2021
Full Text
View/download PDF

49. Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents

Author

UNCU ULU, Bahar, primary, BAKIRTAŞ, Mehmet, additional, YİĞENOĞLU, Tuğçe Nur, additional, BAŞCI, Semih, additional, YILDIZ, Jale, additional, ŞAHİN, Derya, additional, DARÇIN, Tahir, additional, MERDİN, Alparslan, additional, BATGİ, Hikmetullah, additional, İSKENDER, Dicle, additional, BAYSAL, Nuran Ahu, additional, DAL, Sinan, additional, KIZIL ÇAKIR, Merih, additional, and ALTUNTAŞ, Fevzi, additional

Published
2021
Full Text
View/download PDF

50. Consolidation With Autologous Stem Cell Transplantation In Patients With Primary Central Nervous System Lymphoma

Author

Uncu Ulu, Bahar, primary, Şahin, Derya, additional, Yiğenoğlu, Tuğçe Nur, additional, Darçın, Tahir, additional, Bakırtaş, Mehmet, additional, Başcı, Semih, additional, Yıldız, Jale, additional, İskender, Dicle, additional, Baysal, Nuran Ahu, additional, Kızıl Çakar, Merih, additional, Dal, Mehmet Sinan, additional, and Altuntas, Fevzi, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results